The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Phase I trial of ONC201 as post-transplant maintenance for AML and MDS
Vijaya Bhatt, MBBS, University of Nebraska Medical Center, Omaha, NE, discusses the results of a Phase I trial (NCT03932643) evaluating the novel first-in-class agent ONC201 as post-transplant maintenance therapy for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Dr Bhatt highlights the agent’s manageable safety profile, low cytotoxic effect, and promising overall survival (OS) and relapse-free survival (RFS) rates observed in the study. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
